Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Heath, E. I.; Van Veldhuizen, P. J.; Merchan, J. R.; Lang, J. M.; Ruether, J. D.; Petrylak, D. P.; Sangha, R. S.; Smith, D. C.; Sridhar, S. S.; Gartner, E. M.; Vincent, M.; Chu, R.; Anand, B.; Donate, F.; Jackson, L.; Reyno, L. M.; Zhang, J. |
| Abstract Title: | Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 252s |
| Language: | English |
| ACCESSION: | WOS:000404665407106 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.4533 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4533 -- Source: Wos |
